PPIDT00257
Drug Information
| Name | Dulaglutide |
|---|---|
| Sequence | HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG |
| DrugBank_ID | DB09045 |
| Type | biotech |
| Indication | Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.[L30380] It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.[L30380] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
0.75 mg
|
| Injection | Subcutaneous |
1.5 mg
|
| Injection, solution | Parenteral; Subcutaneous |
0.75 MG
|
| Injection, solution | Parenteral; Subcutaneous |
1.5 MG
|
| Injection, solution | Parenteral; Subcutaneous |
3 MG
|
| Injection, solution | Parenteral; Subcutaneous |
4.5 MG
|
| Injection, solution | Subcutaneous |
0.75 mg/0.5mL
|
| Injection, solution | Subcutaneous |
1.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
1.5 MG
|
| Injection, solution | Subcutaneous |
3 mg
|
| Injection, solution | Subcutaneous |
3.0 mg/0.5mL
|
| Injection, solution | Subcutaneous |
4.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
4.5 mg
|
| Solution | Subcutaneous |
0.75 mg / 0.5 mL
|
| Solution | Subcutaneous |
1.5 mg / 0.5 mL
|
| Solution | Subcutaneous |
1.500 mg
|
| Solution | Subcutaneous |
3 mg / 0.5 mL
|
| Solution | Subcutaneous |
4.5 mg / 0.5 mL
|
| Injection, solution | Subcutaneous |
0.75 mg
|
| Solution | Subcutaneous |
0.75 mg
|
| Solution | Subcutaneous |
1.5 mg
|
| Solution | Subcutaneous |
150000 mg
|
| Injection, solution | — |
0.75 mg/0.5ml
|
| Injection, solution | — |
1.5 mg/0.5ml
|